NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN -- Roth Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 13th Annual Roth Technology Conference on November 19-20, 2024, at the Hard Rock Hotel, 159 W 48th St, New York, NY 10036.
The conference will provide pre-qualified institutional investors with the opportunity to network directly with C-level executives from approximately 120 innovative, public and pre-public growth companies, carefully vetted by ROTH's research analysts: Darren Aftahi, Richard Baldry, CFA, Suji Desilva, CFA, Rohit Kulkarni, and Scott Searle, CFA.
The conference will span multiple sub-sectors, including Software and Enterprise Applications; Data, Analytics and AI; Digital Media; Semiconductors and Intelligent Systems; Data Centres and Infrastructure; Wireless, Comms and IoT, and AgTech.
The event will feature 1-on-1 / small group meetings pre-arranged by ROTH’s analysts and gain insights from a special presentation, “Technical Perspective on Global Markets” presented by JC O'Hara - Managing Director, Chief Technical Strategist - ROTH.
This year’s technology conference has expanded significantly, welcoming a record number of companies and participants. Sagar Sheth, Chief Executive Officer of ROTH, emphasized the importance of this event stating, “Technology remains one of the most promising and fascinating areas on the investor community’s radar. With the rapid developments in artificial intelligence, machine learning, cloud computing, and cybersecurity, exploring opportunities and building lasting relationships in this constantly growing industry is increasingly crucial.”
Since 2014, ROTH has been involved in approximately 230 transactions for its technology clients, with a total transaction value of over $16.2 billion. (Source: ROTH | 11/06/2024)
The conference is exclusively for ROTH’s institutional clients and is by invitation only. Prospective attendees are encouraged to contact their ROTH sales representative or email This email address is being protected from spambots. You need JavaScript enabled to view it. to express interest and confirm participation.
TUESDAY | NOVEMBER 19, 2024
12:00 pm - 2:00 pm | Lunch and Registration |
1:00 pm - 4:40 pm | 1-on-1 / Small Group Meetings |
4:45 pm - 5:15 pm | A Technical Perspective on Global Markets with JC O'Hara |
5:30 pm - 8:30 pm | Cocktail Hour with Live Brazilian Music |
WEDNESDAY | NOVEMBER 20, 2024
8:00 am - 9:00 am | Registration and Morning Coffee |
12:00 pm - 2:00 pm | Buffet Lunch |
9:00 am - 5:00 pm | 1-on-1 / Small Group Meetings |
5:00 pm - 6:30 pm | WHAT DOES MUSIC TASTE LIKE RECEPTION |
All times are listed in Eastern Time (EST)
VENUE:
Hard Rock Hotel
159 W 48th St.
New York, NY 10036
Participating Companies at the time of this release include:
List as of 11/06/2024 – subject to change
For b2i company profiles - https://b2idigital.com/roth-13th-annual-technology-conference
Thank you to the event sponsors:
About ROTH
ROTH is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information, please visit www.roth.com.
Investor Contact:
ROTH
Isabel Mattson-Pain
Managing Director, Chief Marketing Officer
949.720.7117, This email address is being protected from spambots. You need JavaScript enabled to view it.
ROTH – Member FINRA/SIPC – www.roth.com
Media Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$2.10 |
Daily Change: | -0.09 -4.11 |
Daily Volume: | 1,938,211 |
Market Cap: | C$348.350M |
December 03, 2024 November 12, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB